287930-77-2

Usage

Uses

A montelukast impurity.

Upstream product

• 165896-48-0 2-[3-(3-bromo-phenyl)-3-oxo-propyl]-benzoic acid methyl ester 
• 181139-72-0 methyl-[(E)]-2-[3(S)-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-hydroxypropyl] benzoate 
• 676-58-4 methylmagnesium chloride 
• 1015076-83-1 sodium 2-[3-(3-bromo-phenyl)-3-oxo-propenyl]-benzoate 
• 177747-94-3 2-[3-(3-bromo-phenyl)-3-oxo-propyl]-benzoic acid 
• 119-67-5 o-carboxybenzaldehyde 
• 2142-63-4 1-(3-Bromophenyl)ethanone 
• 1258428-71-5 trans-1-{3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one 
• 69352-05-2 2-(2-iodophenyl)propan-2-ol 
• 7073-69-0 2-(2-bromophenyl)propanol 
• 610-97-9 o-iodo-methyl-benzoic acid 
• 610-94-6 2-bromobenzoic acid methyl ester 
• 88-67-5 2-Iodobenzoic acid 
• 88-65-3 2-bromobenzoic-acid 

Downstream Products

• 807638-71-7 2-[2-[3(S)-[3-[(1E)-2-(7-chloroquinoline-2-yl)ethenyl]phenyl]-3-methanesulfonyloxypropyl]phenyl]-2-propanol 
• 1003002-64-9 2-(2-(3-(3-((E)-2-(7-chloroquinolin-2-yl)ethenyl)phenyl)-3(S)-(dimethyl(1,1-dimethylethyl)silyloxy)propyl)phenyl)-2-propanol 
• 1266620-74-9 [R,E]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl) ethenyl]phenyl]-3-[2-(hydroxy-1-methylethyl)phenyl]propyl]-sulfonyl]methyl]-cyclopropane acetic acid 
• 855473-51-7 1-(((1(R)-(3-(2(E)-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid methyl ester 
• 918972-54-0 [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-[1-(1-methyl)ethenyl]phenyl]propyl]thio]methyl]cyclopropaneacetic acid 
• 1334676-80-0 [R,E]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[(prop-1-en-2-yl)phenyl]propyl]thio]methyl]cyclopropane acetic acid methyl ester 
• 1351973-25-5 [R,E]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-methoxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropane acetic acid 
• 1197374-11-0 (S)-1-(3-((E)-2-(7-chloroquinolin?2-yl)vinyl)phenyl)-3-(2-isopropenylphenyl)propyl methanesulphonate 
• 1197374-09-6 (S)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-isopropenylphenyl)propyl acetate 
• 1352029-52-7 1R-{(3-[(E)-2-(7-chloroquinolin-2-yl) vinyl] phenyl)}-3-[2-(prop-1-en-2-yl) phenyl] propan-1-ol 
• 1351973-21-1 [S,E]-1-[[[1-[3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl]-3-[2-(prop-1-en-2-yl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid 
• 1351973-22-2 [S,E]-1-[[[1-[3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl]-3-[2-(prop-1-en-2-yl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid dicyclohexylamine salt 
• 151767-02-1 Montelukast sodium 
• 158966-92-8 montelukast 

Relevant academic research and scientific papers

A synthesis process of montelukast sodium (by machine translation)

A synthesis process of montelukast sodium, relates to the field of drug synthesis, adopts a double hydroxy precursor of a sulfonyl derivative, and mercapto carboxylic acid compound, b cyclohexylamine in the reaction under the action of a catalyst, to obtain the ammonium salt, the quaternary ammonium salt is converted into the montelukast sodium. Compared with the direct synthesis of montelukast sodium, synthetic ammonium salt reaction not only conversion is higher, but also easy to separate, high purity, thus being beneficial to obtain high-purity of montelukast sodium. The synthesizing process of the synthetic route is simple, easy to operate, low requirements on equipment, can realize the large-scale production of montelukast sodium. (by machine translation)

A process for the preparation of intermediates Menglusitena

The invention discloses a preparation method of a montelukast sodium intermediate and belongs to the technical fields of pharmaceutical chemicals and biochemical engineering. The preparation method of the montelukast sodium intermediate comprises the foll

An enantioselective formal synthesis of montelukast sodium

A formal synthesis of the antiasthma drug montelukast sodium is described, wherein the key chiral diol intermediate was accessed with greater convergence of the C-C bond-forming steps as compared to previous routes. Improved synthetic efficiency was achie

PREPARATION OF PRECURSORS FOR LEUKOTRIENE ANTAGONISTS

The present invention relates to an improved process for the preparation of a compound having formula (I). The compound having formula (I) is the backbone diol precursor/intermediate used to produce montelukast sodium. Montelukast sodium is a leukotriene

Identification, synthesis and characterization of impurities of Montelukast sodium

Montelukast sodium is a selective leukotriene receptor antagonist which inhibits cysteinyl leukotriene CysLT1 receptor. Various synthesis of Montelukast is published. During laboratory optimization and later in bulk synthesis formation of various impurities was detected. Besides, pharma Europa draft mention nine process related impurities. However, the method of preparation of most of these impurities is not available in literature. Also, different route of synthesis will have different impurity profile and those process related impurities are not covered in pharmacopeias. In this study we report the synthesis of possible process impurities, including seven impurities (A-H) mentioned in pharma Europa.

PREPARATION OF MONTELUKAST

Processes for the preparation of montelukast and its salts.

AN IMPROVED PROCESS FOR THE PREPARATION OF MONTELUKAST SODIUM AND ITS INTERMEDIATES

The present invention relates to a process for the preparation of montelukast sodium (formula 1) and formula 4. The invention concerns the coupling of thiol derivative, Methyl 1 - (mercaptomethyl)cyclopropane acetate with mesylate of formula 4 compound using alkyl substituted ammonium hydroxide base, alkali amides and purification of Montelukast acid by crystallization in suitable organic solvents. The invention further concerns to provide an improved process of montelukast intermediates having good yield and quality

Process and intermediate for the production of an intermediate in the production of montelukast

The tertiary alcohol α-[3-[(1E)2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-2-(1-hydroxy-1-methylethyl)benzenepropanol, the (αS)-enantioner of which is an intermediate in the production of montelukast, is produced by reacting the novel lactone of formula with

Process for the production of tertiary alcohols

Tertiary alcohols are prepared by reacting carboxylic esters with Grignard reagents in ethereal solvents in the presence of lanthanum trichloride and lithium chloride. The method is particularly suitable for the production of (αS)-α-[3-[(1E)-2-(7-chloro-2

SYNTHESIS OF LEUKOTRIENE COMPOUNDS

The present invention relates to the synthesis of leukotriene receptor agonist compounds and to novel intermediates employed in their preparation. Leukotriene agonists are used in the treatment of asthma, as well as other conditions mediated by leukotrienes such as inflammation and allergies. A compound of particular interest is montelukast and the present invention describes an improved process for making montelukast and similar compounds.